GILD34:BVMF
Gilead Sciences Inc BDR
65,81 BRL
0,00%
(0,00) 1 D.
10-16, 16:56:00 GMT−3 · BRL
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „GILD34“ įžvalgos...
Atidaryti
66,36 BRL
Aukšta
66,41 BRL
Žema
65,81 BRL
Rinkos kapitalizacija
193,67 mlrd.
Vid. kiekis
261,00
Apimtis
1,78 tūkst.
52 sav. aukšta
67,38 BRL
52 sav. žema
51,33 BRL
Neapmokėtos akcijos
1,24 mlrd.
Darbuotojų skaičius
17 tūkst.
Atidaryti
66,36 BRL
Aukšta
66,41 BRL
Žema
65,81 BRL
Rinkos kapitalizacija
193,67 mlrd.
Vid. kiekis
261,00
Apimtis
1,78 tūkst.
52 sav. aukšta
67,38 BRL
52 sav. žema
51,33 BRL
Neapmokėtos akcijos
1,24 mlrd.
Darbuotojų skaičius
17 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 3 valandas
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
prieš 4 valandas
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
prieš 22 valandas
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
prieš 1 dieną
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profilis
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Apie „Gilead Sciences Inc BDR“
Generalinis direktoriusDaniel O'Day
Darbuotojai17 tūkst.
Įkurta1987-06-22
Pagrindinė būstinėFoster Sitis, Kalifornija, Jungtinės Valstijos
Sektorius-
Svetainėgilead.com